Table 3

Longitudinal changes of clinical scores in three groups

AT(N)tauMMSEADAS-Cog 13CDR-SBFAQ
Slope (β)P valueFDRSlope (β)P valueFDRSlope (β)P valueFDRSlope (β)P valueFDR
Non-AD pathological changes vs normal biomarkers0.0281.48E-041.48E-040.0130.0080.0080.0314.28.E-044.28E-040.0160.0140.014
AD continuum vs normal biomarkers0.0261.13E-062.26E-060.0181.97E-083.93E-080.0381.39E-092.78E-090.0342.27E-104.54E-10
Non-AD pathological changes vs AD continuum0.0030.8090.8090.0040.6170.6170.0060.6290.6590.0180.1340.134
AT(N)NfLMMSEADAS-Cog 13CDR-SBFAQ
Slope (β)P valueFDRSlope (β)P valueFDRSlope (β)P valueFDRSlope (β)P valueFDR
Non-AD pathological changes vs normal biomarkers0.0120.0340.0340.0090.0120.0120.0130.0640.0640.0110.0190.019
AD continuum vs normal biomarkers0.0261.06E-052.11E-050.0203.46E-086.92E-080.0386.11E-081.22E-070.0352.62E-095.25E-09
Non-AD pathological changes vs AD continuum−0.0130.1200.1200.0090.0780.0780.0250.0150.0230.0240.0057.50E-03
  • Each statistic was calculated by liner mixed model, adjusting age, sexand education years. Bold indicated that the results were statistically significant. The slopes, p values and FDR represent differences between each category.

  • AD, Alzheimer’s disease; ADAS-Cog 13, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; CDR-SB, sum of boxes of the Clinical Dementia Rating; FAQ, Functional Assessment Questionnaire; FDR, false discovery rate; MMSE, Mini-Mental State Examination.